Medulloblastoma is the most common malignant brain tumour in children. Although 70 per cent of children affected by it will be cured, the necessarily aggressive treatments can leave them with significant cognitive disabilities. It is therefore crucial to save the quality of life of medulloblastoma survivors.
In Amin’s first research project funded by Children with Cancer UK, he used an improved version of the technology that he developed at Imperial College London to deliver and target therapeutic nucleic acid sequences to the tumour, resulting in a suppression of medulloblastoma. Moreover, doing so showed how there could be a less damaging new treatment option for young patients with medulloblastoma.
Amin is confident that this product is ready for clinical trials and is keen to see his work helping children in hospitals as soon as possible.
During his work on this project, Amin was awarded the Royal Medal by the King of Morocco for his research into targeted cancer treatments. The Royal Medal is the country’s highest and most coveted official honour.
But Amin did not want to stop there.